Nabota Physician Training Expands Across 11 Countries

Physicians from 11 countries gathered in Bali to compare clinical approaches to the cosmetic injectable.

Updated on Nov. 3, 2026 in Beauty

Bare round wooden table with empty chairs in an open-sided tropical pavilion, palm fronds visible through the openings and a clay vessel on the table.
Daewoong Pharmaceutical hosted 35 physicians from 11 countries in Bali from October 29 to 31 to compare clinical approaches to its Nabota botulinum toxin. AI Illustration. Upload story photo >

Daewoong Pharmaceutical hosted a three-day medical summit in Bali, Indonesia, from October 29 to 31, 2026, bringing together 35 key opinion leaders from 11 countries to discuss Nabota, its botulinum toxin product. The event follows Nabota's cumulative global sales surpassing KRW 1 trillion in June 2026.

Why it matters

For readers considering aesthetic treatments, the summit reflects how a widely used cosmetic injectable is being formally taught and compared across clinicians in different countries. The company said the event was designed to strengthen Nabota's standing in the medical community in line with its sales growth.

The figures come from Daewoong Pharmaceutical's own reporting on Nabota's sales and the summit's attendance rather than from an independent study. The summit itself was a continuing-education gathering, so it does not provide new clinical trial results for the product.

The players

Daewoong Pharmaceutical

A South Korean pharmaceutical company that markets Nabota, a botulinum toxin injectable, and hosted the summit.

Yoon Joon-soo

The leader of Daewoong Pharmaceutical's Nabota Business Division, overseeing the product's commercial and educational programs.

The details

The summit drew physicians from South Korea, Indonesia, Saudi Arabia, and Brazil who presented their treatment experience on the first day, and attendees compared clinical cases and approaches in a roundtable discussion. Training on the second day continued through case-based R.E.A.L. Guidelines, and participants visited BWork Uluwatu and the NULOOK Clinic.

Timeline

  1. June 2026: Nabota's cumulative global sales surpassed KRW 1 trillion.

  2. October 29-31, 2026: The NMC EXCLUSIVE Global KOL Summit Bali 2026 was held in Bali, Indonesia.

Health Landscape

Nabota received FDA approval in 2019 and has since recorded an average annual sales growth rate of 57%, a pace that places it among the faster-growing aesthetic injectables in its category. The summit reflects a broader pattern of manufacturers investing in structured physician training as cosmetic botulinum toxin use expands internationally.

Readers considering cosmetic botulinum toxin treatments may find it worthwhile to ask their clinician about the training and experience of the practitioner providing the injection. Treatment decisions are best made in conversation with a qualified physician who can review your individual health history.

The takeaway

Physician training and transparent clinical experience matter when evaluating cosmetic injectables. Ask your provider about their training and experience before any treatment.

Further reading

For more on the products and treatments shaping this field, explore our Beauty coverage.

Source note: This article includes information reported by Business Korea.